Although this study used similar methodology and models as the work done by Bivona and colleagues [57], this data adds more supporting evidence to lung cancer cells expressing mutant EGFR being dependent on NF-κB signaling for survival; the inhibition by CK1α suppression or other NF-κB signaling components may have a therapeutic benefit in EGFR mutant NSCLC patients. The gene discussed is NFKB1; the disease is non-small cell lung carcinoma.